These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15222254)

  • 1. [Nitric oxide in the physiopathology of myocardial dysfunction in heart failure].
    Brás-Silva C; Leite-Moreira AF
    Rev Port Cardiol; 2004 May; 23 Suppl 2():II105-19. PubMed ID: 15222254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat.
    Bendall JK; Damy T; Ratajczak P; Loyer X; Monceau V; Marty I; Milliez P; Robidel E; Marotte F; Samuel JL; Heymes C
    Circulation; 2004 Oct; 110(16):2368-75. PubMed ID: 15466641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide signaling in the cardiovascular system: implications for heart failure.
    Saraiva RM; Hare JM
    Curr Opin Cardiol; 2006 May; 21(3):221-8. PubMed ID: 16601461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paracrine modulation of heart cell function by endothelial cells.
    Shah AM
    Cardiovasc Res; 1996 Jun; 31(6):847-67. PubMed ID: 8759239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiomyocytes as effectors of nitric oxide signalling.
    Seddon M; Shah AM; Casadei B
    Cardiovasc Res; 2007 Jul; 75(2):315-26. PubMed ID: 17568574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Physiopathology of heart failure].
    Gomes MC; Ferreira A; Bettencourt P
    Rev Port Cardiol; 2004 May; 23 Suppl 2():II7-23. PubMed ID: 15222247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paracrine and autocrine effects of nitric oxide on myocardial function.
    Shah AM; MacCarthy PA
    Pharmacol Ther; 2000 Apr; 86(1):49-86. PubMed ID: 10760546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of nitric oxide/cyclic GMP and cyclic AMP in beta3 adrenoceptor-chronotropic response.
    Sterin-Borda L; Bernabeo G; Ganzinelli S; Joensen L; Borda E
    J Mol Cell Cardiol; 2006 Apr; 40(4):580-8. PubMed ID: 16510153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of the nitric oxide-cGMP pathway exacerbates postischaemic heart injury in stroke-prone hypertensive rats.
    Itoh T; Haruna M; Abe K
    Exp Physiol; 2007 Jan; 92(1):147-59. PubMed ID: 17030559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure.
    Tousoulis D; Charakida M; Stefanadis C
    Int J Cardiol; 2005 Apr; 100(3):347-53. PubMed ID: 15837076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of myocardial nitric oxide in diabetic ischemia-reperfusion dysfunction: studies in mice with myocyte-specific overexpression of endothelial nitric-oxide synthase.
    Pozo-Navas B; Stessel H; Wölkart G; Brunner F
    J Pharmacol Exp Ther; 2006 Nov; 319(2):729-38. PubMed ID: 16857730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide and cardiac function.
    Rastaldo R; Pagliaro P; Cappello S; Penna C; Mancardi D; Westerhof N; Losano G
    Life Sci; 2007 Aug; 81(10):779-93. PubMed ID: 17707439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 prevents myocardial dysfunction in murine models of septic shock.
    Ichinose F; Buys ES; Neilan TG; Furutani EM; Morgan JG; Jassal DS; Graveline AR; Searles RJ; Lim CC; Kaneki M; Picard MH; Scherrer-Crosbie M; Janssens S; Liao R; Bloch KD
    Circ Res; 2007 Jan; 100(1):130-9. PubMed ID: 17138944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Traumatic injury of the spinal cord and nitric oxide.
    Marsala J; Orendácová J; Lukácová N; Vanický I
    Prog Brain Res; 2007; 161():171-83. PubMed ID: 17618976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory mediators and reversible myocardial dysfunction.
    Kan H; Finkel MS
    J Cell Physiol; 2003 Apr; 195(1):1-11. PubMed ID: 12599203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
    Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
    Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the nitric oxide-cGMP pathway in the cardiovascular effects of anesthetic agents: a review.
    Lecomte PV; De Mulder PA; Adriaensen HF; De Hert SG
    Acta Anaesthesiol Belg; 1999; 50(3):105-12. PubMed ID: 10529847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of nitric oxide in mediating cardiovascular alterations accompanying heart failure in rats.
    da Cunha V; Stefanon I; Mill JG
    Can J Physiol Pharmacol; 2004 Jun; 82(6):372-9. PubMed ID: 15381960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myocardial effects of nitric oxide, NO. Clinical and experimental evidence].
    Heymes C; Swynghedauw B; Samuel JL
    Bull Acad Natl Med; 2005 May; 189(5):893-901; discussion 901. PubMed ID: 16433461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.